Published in Br J Cancer on July 14, 2015
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 7.30
Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res (2007) 3.49
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
VEGF receptor signaling in tumor angiogenesis. Oncologist (2000) 1.94
Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol (2011) 1.70
A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol (2011) 1.58
HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg (2009) 1.49
Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck (2010) 1.46
Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res (2004) 1.44
Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol (1999) 1.41
Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene (2012) 1.37
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2003) 1.33
De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer (2014) 1.18
Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol (2004) 1.13
Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. J Exp Clin Cancer Res (2004) 1.01
Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Ann Oncol (2013) 0.89
Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis. Tumour Biol (2014) 0.89
Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer. Mol Cancer (2014) 0.88
HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches. Cancer Lett (2014) 0.85
Circulating Thrombospondin-2 and FGF-2 in Patients with Advanced Non-small Cell Lung Cancer: Correlation with Survival. Adv Exp Med Biol (2015) 0.82
Accurate HPV testing: a requirement for precision medicine for head and neck cancer. Ann Oncol (2013) 0.82
Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers. Br J Cancer (2014) 0.81
Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol Ther (2014) 0.81
Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters. Hepatogastroenterology (2006) 0.80